Lansoprazole has not been linked to an increased risk of birth defects, miscarriage, or preterm delivery based on available evidence. It carries a Pregnancy Category B rating from the FDA, meaning animal studies showed no harm to the fetus and the limited human data available is reassuring. That said, it’s typically reserved for pregnant women whose acid reflux hasn’t responded to simpler treatments.
What the Safety Data Shows
Animal studies tested lansoprazole at doses up to 40 times the recommended human dose in rats and 16 times in rabbits, with no evidence of harm to the fetus or impaired fertility. Human data, while more limited, points in the same direction.
A prospective cohort study from Japan followed 106 pregnancies exposed to lansoprazole during the first trimester and compared them to 1,788 unexposed pregnancies. The rate of major birth defects was 1.0% in the lansoprazole group versus 1.9% in the control group. That 1.0% rate falls well below the general population baseline of 3 to 5%. Researchers found no significant difference in stillbirth, miscarriage, or birth weight between the two groups either.
A broader meta-analysis pooling data from 1,530 pregnant women who took proton pump inhibitors (the drug class lansoprazole belongs to) during at least the first trimester found an odds ratio for congenital malformation of 1.12, which was not statistically significant. There was also no meaningful increase in spontaneous abortion or preterm delivery.
First Trimester Exposure
The first trimester is the period of greatest concern with any medication because that’s when a baby’s organs are forming. The Japanese cohort study specifically focused on first-trimester lansoprazole exposure and concluded it was not associated with increased risk of major malformations. This is particularly reassuring because many women take lansoprazole before realizing they’re pregnant, and the data suggests that early exposure does not appear to cause harm.
Potential Effects on the Child Later in Life
Some parents worry about subtler, longer-term effects on children exposed to acid-suppressing medications in the womb. A large cohort study published in JAMA Pediatrics looked at whether prenatal exposure to these drugs raised the risk of allergic conditions like asthma, allergic rhinitis, eczema, or food allergies. The initial analysis found hazard ratios extremely close to 1.0 for all conditions, and when researchers compared siblings (one exposed, one not) the results were not statistically significant. In practical terms, there’s no convincing evidence that taking lansoprazole during pregnancy increases your child’s risk of allergic disease.
Where Lansoprazole Fits in Pregnancy Treatment
Heartburn and acid reflux affect a large proportion of pregnancies, especially in the second and third trimesters. Clinical guidelines recommend a step-up approach rather than jumping straight to lansoprazole or other proton pump inhibitors.
The typical sequence looks like this:
- Lifestyle changes first: smaller meals, avoiding eating close to bedtime, elevating the head of your bed, and steering clear of trigger foods like spicy or fatty dishes.
- Calcium-based antacids: these are considered the safest first medication and can be taken as needed.
- Sucralfate: a mucosal protectant that can be added if antacids alone aren’t enough.
- H2 blockers: a step up from antacids, these reduce acid production and have a strong safety profile in pregnancy.
- Proton pump inhibitors (like lansoprazole): reserved for when the above options haven’t controlled symptoms adequately.
This doesn’t mean lansoprazole is dangerous. It means that for most pregnant women, milder options resolve the problem, and there’s simply more safety data behind antacids and H2 blockers. If your reflux is severe enough that those aren’t working, lansoprazole is a reasonable next step.
Standard Dosing
There is no separate pregnancy-specific dose for lansoprazole. The standard approach for reflux symptoms is 15 mg once daily for up to 8 weeks. For more severe cases involving erosion of the esophageal lining, the dose is 30 mg once daily for up to 8 weeks. Your prescriber will aim for the lowest effective dose for the shortest time needed.
Lansoprazole While Breastfeeding
There are no published studies measuring lansoprazole levels in human breast milk. However, lansoprazole has been used safely in newborn infants directly, which suggests that the small amounts that might pass through breast milk are unlikely to cause harm. The LactMed database, maintained by the National Institutes of Health, notes this point but acknowledges the gap in direct breastfeeding data.